Patents by Inventor Marc F. Charette
Marc F. Charette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7507709Abstract: OP/BMP morphogen may be combined with GDNF/NGF neurotrophic factors to promote the survival or growth, or inhibit the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also disclosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.Type: GrantFiled: March 18, 2005Date of Patent: March 24, 2009Assignee: Stryker CorporationInventors: Marc F. Charette, Ted Ebendal, David C. Rueger
-
Patent number: 7105638Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.Type: GrantFiled: February 4, 1993Date of Patent: September 12, 2006Assignee: Micromet AGInventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
-
Patent number: 7060680Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: January 15, 2002Date of Patent: June 13, 2006Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 6936582Abstract: OP/BMP morphogen is combined with GDNF/NGF neurotrophic factors in promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also discosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.Type: GrantFiled: September 9, 1998Date of Patent: August 30, 2005Assignee: Curis, Inc.Inventors: Marc F. Charette, Ted Ebendal, David C. Rueger
-
Publication number: 20040176292Abstract: Disclosed are methods and compositions for protecting cognitive function in a mammal, particularly a human, subject to brain tissue damage, by administering a morphogen or a nucleic acid encoding a morphogen to the mammal. The methods and compositions can be used to reduce memory dysfunction and/or to provide a neuroprotective effect in subjects at risk of memory dysfunction resulting from mechanical or chemical trauma, neuropathies, neurodegenerative diseases, or oxygen or glucose deprivation.Type: ApplicationFiled: December 12, 2003Publication date: September 9, 2004Inventor: Marc F. Charette
-
Publication number: 20030170213Abstract: Disclosed are methods and compositions for protecting cognitive function in a mammal, particularly a human, subject to brain tissue damage, by administering a morphogen or a nucleic acid encoding a morphogen to the mammal. The methods and compositions can be used to reduce memory dysfunction and/or to provide a neuroprotective effect in subjects at risk of memory dysfunction resulting from mechanical or chemical trauma, neuropathies, neurodegenerative diseases, or oxygen or glucose deprivation.Type: ApplicationFiled: January 23, 1998Publication date: September 11, 2003Inventor: MARC F. CHARETTE
-
Publication number: 20030125230Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: ApplicationFiled: January 15, 2002Publication date: July 3, 2003Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H.L. Pang, Engin Ozkaynak, John E. Smart
-
Publication number: 20030022830Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.Type: ApplicationFiled: February 1, 2002Publication date: January 30, 2003Inventors: Marc F. Charette, Seth P. Finklestein
-
Patent number: 6407060Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.Type: GrantFiled: March 21, 1997Date of Patent: June 18, 2002Assignee: Curis, Inc.Inventors: Marc F. Charette, Seth P. Finklestein
-
Patent number: 6399569Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: June 4, 2002Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 5972884Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: October 26, 1999Assignee: Creative BioMolecules, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang
-
Patent number: 5759815Abstract: Native, analog, and mutein species of A and B chains of platelet derived growth factor are produced in prokaryotes, purified, combined, and modified in vitro to produce various active AA, AB, and BB PDGF dimers.Type: GrantFiled: May 6, 1991Date of Patent: June 2, 1998Assignee: Creative BioMolecules, Inc.Inventors: Marc F. Charette, Zita A. Babickas, Hermann Oppermann
-
Patent number: 5739107Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: Creative BioMolecules, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 5416007Abstract: Disclosed are methods for increasing the yield of intact target proteins by cleaving fused polypeptides made by recombinant DNA techniques. The fused polypeptides are designed at the DNA level to have a preselected primary cleavage site in a pendant polypeptide fused to a protein of interest. Structural features of the fused polypeptide and cleavage reaction environment are controlled to favor cleavage by a preselected cleavage agent at the primary cleavage site over a second cleavage agent-sensitive amino acid sequence in the target protein. The cleavage reaction is terminated before completion when the ratio of intact target protein to truncated, cleaved target protein is optimized, and the remaining reaction mixture comprising uncleaved fused polypeptide is resubjected to the cleavage agent. The presence of charged organic molecules in the cleavage reaction mixture favors cleavage at the primary cleavage site. The endopeptidase used for cleavage may be immobilized on an insoluble support matrix.Type: GrantFiled: July 12, 1994Date of Patent: May 16, 1995Assignee: Creative BioMolecules, Inc.Inventors: Marc F. Charette, Roberto Crea, Charles M. Cohen
-
Patent number: 5376636Abstract: Disclosed is a method for the regeneration of tissue, the treatment of external wounds and the treatment of periodontal disease comprising applying to the affected tissue an effective amount of a composition comprised of platelet-derived growth factor (PDGF) and an anti-inflammatory compound. The presence of the anti-inflammatory compound potentiates the activity of PDGF in stimulating cell growth, thereby enhancing tissue regeneration and/or wound healing.Type: GrantFiled: March 12, 1992Date of Patent: December 27, 1994Assignees: Creative BioMolecules, Inc., The University of Conn.Inventors: Robert B. Rutherford, Marc F. Charette
-
Patent number: 5234908Abstract: Disclosed is a method for treating ulcers of the gastrointestinal tract in a mammal which includes administering to the mammal a therapeutically effective amount of Platelet-Derived Growth Factor (PDGF) to the gastrointestinal tract of the mammal.Type: GrantFiled: April 10, 1992Date of Patent: August 10, 1993Assignees: Creative BioMolecules, Inc., Brigham & Womens HospitalInventors: Sandor Szabo, Marc F. Charette
-
Patent number: 5013653Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.Type: GrantFiled: December 28, 1989Date of Patent: May 7, 1991Assignee: Creative Biomolecules, Inc.Inventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
-
Patent number: 4590159Abstract: Endogenous and exogenous gene directed expression of protein synthesis in Escherichia coli is enhanced by transformation to incorporate a dominant mucoid mutant allele of the capR (lon) gene, preferably through use of the DNA plasmid, pBZ201M9 (A.T.C.C. Plasmid No. 40041) which carries the capR9 mutant allele.Type: GrantFiled: August 17, 1983Date of Patent: May 20, 1986Assignee: University Patents, Inc.Inventors: Alvin Markovitz, Barbara A. Zehnbauer, Joyce M. Schoemaker, Marc F. Charette